{"publisher":"CagriSema Rx","product":"CagriSema","preparedAt":"2026-11-07","reviewStatus":"Research drafts; medical review has not been claimed","facts":[{"label":"Research finding 1","text":"REDEFINE1 randomized 3417 adults with overweight/obesity without diabetes to combination, either component, or placebo, all with lifestyle support, for 68 weeks.","href":"https://pubmed.ncbi.nlm.nih.gov/40544433/"},{"label":"Research finding 2","text":"In REDEFINE1, mean weight change using the treatment-policy estimand was−20.4% with the combination versus−3.0% with placebo; estimated difference−17.3 percentage points.","href":"https://pubmed.ncbi.nlm.nih.gov/40544433/"},{"label":"Research finding 3","text":"Gastrointestinal adverse events occurred in 79.6% of combination recipients versus 39.9% of placebo recipients in REDEFINE1.","href":"https://pubmed.ncbi.nlm.nih.gov/40544433/"},{"label":"Research finding 4","text":"REDEFINE2 randomized 1206 adults with type 2 diabetes and BMI≥27; mean week 68 weight change was−13.7% versus−3.4% with placebo.","href":"https://pubmed.ncbi.nlm.nih.gov/40544432/"}],"sources":[{"title":"Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity.","href":"https://pubmed.ncbi.nlm.nih.gov/40544433/"},{"title":"Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes.","href":"https://pubmed.ncbi.nlm.nih.gov/40544432/"},{"title":"FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss","href":"https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss"}],"guides":[{"title":"What cagrilintide-alone research adds to the CagriSema story","url":"https://cagrisemarx.com/research-guides/cagrilintide-alone-phase-two-comparison","description":"Read the 26-week monotherapy trial as evidence about a component, with its own comparator and analysis assumptions.","date":"2026-11-07"},{"title":"Cagrilintide, semaglutide and CagriSema: verify the intervention first","url":"https://cagrisemarx.com/research-guides/cagrilintide-versus-cagrisema-identity","description":"A product-identity framework for understanding combination research without transferring results to different mixtures or single agents.","date":"2026-11-07"},{"title":"CagriSema and blood pressure: why medication review is a separate decision","url":"https://cagrisemarx.com/research-guides/cagrisema-blood-pressure-medication-review","description":"Interpret the REDEFINE 1 blood-pressure analysis without treating it as permission to stop an antihypertensive medicine.","date":"2026-11-07"},{"title":"Would CagriSema evidence change your treatment discussion?","url":"https://cagrisemarx.com/research-guides/cagrisema-comparison-consultation-questions","description":"Use comparator, endpoint, added benefit and remaining uncertainty to prepare a precise conversation about combination research.","date":"2026-11-07"},{"title":"CagriSema with type 2 diabetes: which trial answers which question?","url":"https://cagrisemarx.com/research-guides/cagrisema-diabetes-trial-results","description":"Distinguish REDEFINE 2, REIMAGINE 2 and the earlier phase 2 study when weighing glucose and weight outcomes.","date":"2026-11-07"},{"title":"Does CagriSema prevent heart attacks? Do not transfer a component’s result","url":"https://cagrisemarx.com/research-guides/cagrisema-heart-outcomes-evidence-boundary","description":"Distinguish blood-pressure findings from cardiovascular-event trials and keep semaglutide-specific evidence attached to its tested intervention.","date":"2026-11-07"},{"title":"What REDEFINE 5 contributes for readers in Japan and Taiwan","url":"https://cagrisemarx.com/research-guides/cagrisema-japan-taiwan-redefine-five","description":"Examine the regional trial’s active comparator, eligibility and analysis before applying its results to a broader population.","date":"2026-11-07"},{"title":"CagriSema maintenance and dose reduction: read a study plan as a plan","url":"https://cagrisemarx.com/research-guides/cagrisema-maintenance-lower-dose-redefine-eight","description":"What the REDEFINE 8 registry can tell you about the question being tested, and why it cannot supply a tapering regimen.","date":"2026-11-07"},{"title":"How to read CagriSema’s side-effect numbers","url":"https://cagrisemarx.com/research-guides/cagrisema-tolerability-safety-numbers","description":"Distinguish event counts, affected participants, severity and unanswered safety questions in combination trials.","date":"2026-11-07"},{"title":"Can you obtain CagriSema in the United States? Check status before price","url":"https://cagrisemarx.com/research-guides/cagrisema-us-access-compounding-status","description":"A November 2026 framework for separating trial participation, approved medicines and claims about compounded cagrilintide.","date":"2026-11-07"},{"title":"Beyond percentage weight loss: reading CagriSema’s waist and BMI analysis","url":"https://cagrisemarx.com/research-guides/cagrisema-waist-height-bmi-targets","description":"Understand absolute body-size targets and why a post hoc association is not a personalized treatment threshold.","date":"2026-11-07"},{"title":"What CagriSema’s 20.4% result actually measures","url":"https://cagrisemarx.com/research-guides/redefine-one-weight-loss-estimand","description":"Read REDEFINE 1 through its population, comparator, timeframe and treatment-policy estimate before using a weight-loss headline.","date":"2026-11-07"}]}